Valuation : TG Therapeutics, Inc.

Market Cap 7.65B 6.59B 6.18B 5.65B 10.61B 728B 10.68B 73.28B 28.51B 369B 28.72B 28.1B 1,222B P/E 2026 *
57x
P/E 2027 * 18.8x
Enterprise Value 7.82B 6.73B 6.32B 5.77B 10.84B 744B 10.92B 74.9B 29.14B 377B 29.36B 28.72B 1,249B EV / Sales 2026 *
8.14x
EV / Sales 2027 * 5.54x
Free-Float
88.56%
Yield 2026 *
-
Yield 2027 * -
1 day-1.05%
1 week-5.20%
Current month+2.06%
1 month+2.06%
3 months+41.94%
6 months+83.86%
Current year+78.13%
1 week 52.67
Extreme 52.67
57.9
1 month 45.36
Extreme 45.365
57.9
Current year 26.76
Extreme 26.76
59.3
1 year 26.76
Extreme 26.76
59.3
3 years 6.46
Extreme 6.46
59.3
5 years 3.48
Extreme 3.48
59.3
10 years 3.32
Extreme 3.32
59.3
Manager TitleAgeSince
Chief Executive Officer 60 29/12/2011
Director of Finance/CFO 44 29/12/2011
Investor Relations Contact - 01/12/2011
Director TitleAgeSince
Chairman 60 29/12/2011
Director/Board Member 79 01/03/2012
Director/Board Member 62 09/11/2012
Date Insider Type Main position Quantity % Market Cap. Importance
8/7/26 A Don

Director

-950 0.0006%
1/28/26 A Don

Director

43,197 0.0272%
1/8/26 A Free

Chief Executive Officer

622,000 0.3918%
Change 5-day change 1-year change 3-year change Capi.($)
-1.05%-5.20%+78.61%+407.16% 7.65B
-1.67%-7.37%+57.10%+108.41% 1,047B
-0.65%-2.51%+49.49%+64.63% 646B
+0.50%-3.01%+21.07%+74.58% 451B
-1.64%-4.75%+35.59%+35.54% 355B
-0.39%-2.76%+21.39%+38.01% 291B
-1.19%-2.21%+1.53%+11.51% 252B
-0.48%-3.03%+50.00%+67.89% 234B
-1.05%-2.29%-19.91%-54.10% 203B
+0.40%-0.25%+29.87%+91.39% 181B
Average -0.84%-2.47%+32.47%+84.50% 366.69B
Weighted average by Cap. -0.99%-3.45%+36.58%+65.45%

Financials

2026 *2027 *
Net sales 960M 827M 776M 709M 1.33B 91.36B 1.34B 9.2B 3.58B 46.33B 3.61B 3.53B 153B 1.32B 1.13B 1.07B 973M 1.83B 125B 1.84B 12.63B 4.91B 63.59B 4.95B 4.84B 211B
Net income 157M 136M 127M 116M 218M 14.98B 220M 1.51B 587M 7.59B 591M 578M 25.15B 450M 388M 364M 332M 624M 42.83B 629M 4.31B 1.68B 21.72B 1.69B 1.65B 71.91B
Net Debt 169M 146M 137M 125M 234M 16.08B 236M 1.62B 630M 8.15B 635M 621M 27B -348M -300M -281M -257M -482M -33.11B -486M -3.33B -1.3B -16.79B -1.31B -1.28B -55.6B
Logo TG Therapeutics, Inc.
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
Employees
399
Date Price Change Volume
31/08/26 $53.10 -1.54% 441,537
28/08/26 $53.93 -3.21% 1,030,762
27/08/26 $55.72 +1.25% 1,222,502
26/08/26 $55.03 -0.70% 963,307
25/08/26 $55.42 -1.05% 1,991,544
Trader
Investor
Global
Quality
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
53.93USD
Average target price
69.71USD
Spread / Average Target
+29.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TGTX Stock